BioCryst Pharmaceuticals IncNASDAQ:BCRX
- LAST PRICE4.6700
- TODAY'S CHANGE (%)0.0900 (1.9651%)
- Bid / Lots4.6600/ 24
- Ask / Lots4.6700/ 16
- Open / Previous Close4.6000 / 4.5800
- Day Range
- 52 Week Range
- Volume446,011
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BCRX |
|---|---|---|
| 09:32 ET | 32851 | 4.59 |
| 09:34 ET | 600 | 4.62 |
| 09:36 ET | 4649 | 4.58 |
| 09:38 ET | 2039 | 4.57 |
| 09:39 ET | 6521 | 4.575 |
| 09:41 ET | 6438 | 4.575 |
| 09:43 ET | 1172 | 4.585 |
| 09:45 ET | 3138 | 4.55 |
| 09:48 ET | 48965 | 4.565 |
| 09:50 ET | 17860 | 4.5499 |
| 09:52 ET | 14213 | 4.555 |
| 09:54 ET | 1100 | 4.55 |
| 09:56 ET | 28754 | 4.61 |
| 09:57 ET | 8517 | 4.605 |
| 09:59 ET | 5130 | 4.58 |
| 10:01 ET | 8927 | 4.57 |
| 10:03 ET | 15857 | 4.565 |
| 10:06 ET | 22909 | 4.56 |
| 10:08 ET | 6261 | 4.56 |
| 10:10 ET | 39954 | 4.58 |
| 10:12 ET | 11814 | 4.605 |
| 10:14 ET | 5577 | 4.62 |
| 10:15 ET | 2395 | 4.62 |
| 10:17 ET | 8603 | 4.64 |
| 10:19 ET | 1789 | 4.645 |
| 10:21 ET | 3394 | 4.65 |
| 10:24 ET | 17826 | 4.63 |
| 10:26 ET | 5325 | 4.64 |
| 10:28 ET | 8417 | 4.65 |
| 10:30 ET | 3410 | 4.65 |
| 10:32 ET | 3561 | 4.635 |
| 10:33 ET | 600 | 4.63 |
| 10:35 ET | 1500 | 4.635 |
| 10:37 ET | 1617 | 4.645 |
| 10:39 ET | 800 | 4.64 |
| 10:42 ET | 6031 | 4.625 |
| 10:44 ET | 10021 | 4.64 |
| 10:46 ET | 4780 | 4.65 |
| 10:48 ET | 3439 | 4.625 |
| 10:50 ET | 4947 | 4.64 |
| 10:51 ET | 1000 | 4.645 |
| 10:53 ET | 200 | 4.64 |
| 10:55 ET | 822 | 4.65 |
| 10:57 ET | 400 | 4.645 |
| 11:00 ET | 17046 | 4.67 |
Yesterday
BioCryst Announces Approval of ORLADEYO(R) (berotralstat) by the Brazilian Health Regulatory Agency, from 4:30AM ET on Wednesday Apr 17, 2024 by Dow Jones
4:30AM ET on Wednesday Apr 17, 2024 by Dow Jones
Apr 10, 2024
DJ BioCryst Pharmaceuticals Price Target Maintained With a $12.00/Share by Needham, from 7:19AM ET on Wednesday Apr 10, 2024 by Dow Jones
7:19AM ET on Wednesday Apr 10, 2024 by Dow Jones
Apr 3, 2024
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 7:00AM ET on Wednesday Apr 03, 2024 by Dow Jones
7:00AM ET on Wednesday Apr 03, 2024 by Dow Jones
Mar 25, 2024
BioCryst to Present at Upcoming Investor Conferences, from 4:01PM ET on Monday Mar 25, 2024 by Dow Jones
4:01PM ET on Monday Mar 25, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioCryst Pharmaceuticals Inc | 944.2M | -4.0x | --- |
MiMedx Group Inc | 930.2M | 24.7x | --- |
Kiniksa Pharmaceuticals Ltd | 1.2B | 106.0x | --- |
Veracyte Inc | 1.5B | -18.8x | --- |
Amarin Corporation PLC | 376.6M | -6.2x | --- |
CareDx Inc | 428.7M | -2.4x | --- |
Company Information
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
Contact Information
- Headquarters
- 4505 Emperor Blvd Ste 200DURHAM, NC, United States 27703-8457
- Phone
- 919-859-1302
- Fax
- 919-859-1314
Executives
- Independent Chairman of the Board
- Nancy Hutson
- President, Chief Executive Officer, Director
- Jon Stonehouse
- Chief Financial Officer
- Anthony Doyle
- Chief Commercial Officer
- Charles Gayer
- Chief Research & Development Officer
- Helen Thackray
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $944.2M |
|---|---|
Revenue (TTM) | $331.4M |
Shares Outstanding | 206.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.93 |
EPS | $-1.18 |
Book Value | $-2.21 |
P/E Ratio | -4.0x |
Price/Sales (TTM) | 2.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40.05% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
